No profile data available.
MeiraGTx Holdings plc (MGTX) is a healthcare company in the eye treatment pharmaceuticals industry, based in New York, United States, with about 393 full-time employees.
It reported revenue of $81.39 million for fiscal year 2025, up 144.6% from fiscal year 2024, and net income of -$114.20 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $321.43 million, up 8608.6% from a year before. Its market capitalization was $1.05 billion as of October 5, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 5, 2026.
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
MeiraGTx Holdings reported $81.39 million in revenue for fiscal year 2025, up 144.6% from $33.28 million in fiscal year 2024. In Q2 2026 revenue was $321.43 million.
$1.05 billion as of October 5, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Belite Bio, Inc (BLTE), Bausch + Lomb Corporation (BLCO), Kodiak Sciences Inc. (KOD), Opus Genetics, Inc. (IRD).